PortfoliosLab logo
AVITA Medical, Inc. (RCEL)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US05380C1027

CUSIP

05380C102

IPO Date

Oct 1, 2019

Highlights

Market Cap

$191.65M

EPS (TTM)

-$2.39

Total Revenue (TTM)

$71.66M

Gross Profit (TTM)

$61.25M

EBITDA (TTM)

-$38.24M

Year Range

$6.60 - $14.16

Target Price

$16.05

Short %

11.34%

Short Ratio

15.54

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
RCEL vs. ORI RCEL vs. O
Popular comparisons:

Performance

Performance Chart


Loading data...

Returns By Period

AVITA Medical, Inc. (RCEL) returned -45.23% year-to-date (YTD) and -16.05% over the past 12 months.


RCEL

YTD

-45.23%

1M

-18.68%

6M

-44.63%

1Y

-16.05%

5Y*

-25.81%

10Y*

N/A

^GSPC (Benchmark)

YTD

0.08%

1M

9.75%

6M

-1.63%

1Y

12.74%

5Y*

15.66%

10Y*

10.77%

*Annualized

Monthly Returns

The table below presents the monthly returns of RCEL, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-28.91%-0.00%-10.55%19.04%-27.66%-45.23%
202422.16%8.17%-11.58%-47.60%14.40%-17.59%23.74%-4.49%14.53%-5.78%26.93%-0.16%-6.71%
202341.52%43.58%4.18%11.10%-26.42%48.95%19.05%-19.51%-10.37%-36.28%14.50%28.71%107.88%
2022-19.28%-4.86%-7.83%-28.07%-6.56%-16.67%18.53%9.77%-14.72%-7.21%35.99%-0.75%-44.91%
202132.88%-11.95%-8.83%4.14%-12.50%13.62%-9.70%9.07%-12.32%-7.05%-16.45%-12.94%-35.52%
2020-6.04%-10.06%-19.38%-2.26%6.27%-5.16%-28.72%17.73%-1.83%-18.60%5.57%-14.06%-59.16%
20198.96%3.75%6.06%19.89%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of RCEL is 37, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of RCEL is 3737
Overall Rank
The Sharpe Ratio Rank of RCEL is 3939
Sharpe Ratio Rank
The Sortino Ratio Rank of RCEL is 4040
Sortino Ratio Rank
The Omega Ratio Rank of RCEL is 4040
Omega Ratio Rank
The Calmar Ratio Rank of RCEL is 3636
Calmar Ratio Rank
The Martin Ratio Rank of RCEL is 3030
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for AVITA Medical, Inc. (RCEL) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

AVITA Medical, Inc. Sharpe ratios as of May 14, 2025 (values are recalculated daily):

  • 1-Year: -0.21
  • 5-Year: -0.38
  • All Time: -0.37

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of AVITA Medical, Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


AVITA Medical, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the AVITA Medical, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AVITA Medical, Inc. was 91.79%, occurring on Oct 14, 2022. The portfolio has not yet recovered.

The current AVITA Medical, Inc. drawdown is 87.30%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-91.79%Feb 20, 2020670Oct 14, 2022
-26.8%Nov 13, 20197Nov 21, 201935Jan 14, 202042
-17.63%Jan 17, 202010Jan 31, 20207Feb 11, 202017
-15.26%Oct 24, 20195Oct 30, 20196Nov 7, 201911
-6.19%Oct 2, 20191Oct 2, 20197Oct 11, 20198

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of AVITA Medical, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of AVITA Medical, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -159.0%.


-0.80-0.60-0.40-0.200.0020212022202320242025
-0.83
-0.32
Actual
Estimate

Valuation

The Valuation section provides an overview of how AVITA Medical, Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for RCEL relative to other companies in the Medical Devices industry. Currently, RCEL has a P/S ratio of 2.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for RCEL in comparison with other companies in the Medical Devices industry. Currently, RCEL has a P/B value of 55.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items